Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

You still haven't provided a single study for your...

User Euphoric-War-3117, in the PeterAttia subreddit, 19 Aug 2026

You still haven't provided a single study for your claims. Here you go: **Claim 1:** Achieving very low circulating LDL…

That’s not what FOURIER Evolocumab reduced the...

User LongjumpingPut7437, in the PeterAttia subreddit, 12 Aug 2026

That’s not what FOURIER showed. Evolocumab reduced the primary cardiovascular endpoint by 15% (HR 0.85, 95% CI 0.79–0.92) and…

The FOURIER and ODYSSEY OUTCOMES trials, both published in...

User SunniePie, in the Health subreddit, 27 Jul 2026

The FOURIER and ODYSSEY OUTCOMES trials, both published in [The New England Journal of Medicine](https://diabetesjournals.org/car…

The FDA just approved the first oral PCSK9 inhibitor. It drops LDL about 56%, same ballpark as the injections — here's who actually needs it (and who mostly doesn't)

User DadStrengthDaily, in the ProactiveHealth subreddit, 16 Jul 2026